Drotrecogin alfa (activated) (Xigris, marketed by Eli Lilly and Company) is a recombinant form of human activated protein C that has anti-thrombotic, anti-inflammatory... 15 KB (1,675 words) - 19:31, 20 December 2023 |
activated protein C, was produced in recombinant form and marketed as Drotrecogin alfa (also known as Xigris (TM)) and licensed for intensive-care treatment... 12 KB (1,339 words) - 16:56, 29 June 2023 |
Archived from the original on 1 February 2014. Retrieved 26 January 2014. Drotrecogin Alfa (Activated) in Adults with Septic Shock Archived 2015-09-29 at the... 46 KB (1,956 words) - 13:53, 13 April 2024 |
wafer chemotherapy Interstitial/ intracavitary (00.11) Infusion of drotrecogin alfa (activated) Infusion of recombinant protein (00.12) Administration... 107 KB (9,048 words) - 08:37, 21 March 2024 |
drospirenone (INN) drostanolone (INN) drotaverine (INN) drotebanol (INN) drotrecogin alfa (INN) droxacin (INN) Droxia droxicainide (INN) droxicam (INN) droxidopa... 5 KB (288 words) - 22:10, 23 March 2024 |
B01AD09 Ancrod B01AD10 Drotrecogin alfa (activated) B01AD11 Tenecteplase B01AD12 Protein C B01AD13 Apadamtase alfa and cinaxadamtase alfa B01AE01 Desirudin... 3 KB (346 words) - 19:19, 12 March 2024 |